Amylmetacresol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Amylmetacresol
- Pharmacist Assessment Report
- Amylmetacresol: From Throat Antiseptic Lozenges to Cauda Equina Syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Amylmetacresol: From Throat Antiseptic Lozenges to Cauda Equina Syndrome
One-Sentence Summary
Amylmetacresol is a locally acting antiseptic marketed in Canada in throat lozenges (the Health Canada licence data compiled for this report does not list a formal approved-indication text). The TxGNN model predicts it may be effective for cauda equina syndrome, but this is a computational prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence data (marketed as an antibacterial throat lozenge) |
| Predicted New Indication | Cauda equina syndrome |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Amylmetacresol is known as a topical antiseptic used in throat lozenges. Its pharmacological action in cauda equina syndrome has not been established.
The link between the original use (local oropharyngeal infection and soreness) and the predicted indication is weak. Cauda equina syndrome is a compressive neurological condition of the lower spinal nerve roots. A mild local anesthetic-like effect (possibly sodium channel blockade) is speculative and would not plausibly address nerve compression. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, rather than a verified pharmacological rationale.
Other top-ranked predictions are also unsupported by evidence:
| Rank | Predicted Indication | TxGNN Score | Evidence Level |
|---|---|---|---|
| 2 | Neurogenic bladder (obsolete ontology term) | 0.9996 | L5 |
| 3 | Irritable bowel syndrome | 0.9989 | L5 |
| 4 | Ciliary body disease | 0.9970 | L5 |
| 5 | Panuveitis | 0.9968 | L5 |
| 6 | Iris disease | 0.9963 | L5 |
| 7 | Infectious anterior uveitis | 0.9957 | L5 |
| 8 | Uveitis | 0.9953 | L5 |
| 9 | Ciliary body cancer | 0.9946 | L5 |
| 10 | Benign neoplasm of ciliary body | 0.9945 | L5 |
The only weakly plausible rationale among these is infectious anterior uveitis, based on in vitro antibacterial and antiviral activity. There is no evidence of intraocular penetration, efficacy or ocular safety, and established pathogen-directed therapy is far better supported.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02375567 | Antibacterial Throat Lozenges | Not stated | Not stated |
| 02382938 | Cepacol Sensations | Not stated | Not stated |
| 02404982 | Cepacol Children’s Fruity Strawberry | Not stated | Not stated |
| 02388642 | Cepacol Sensations Sore Throat & Cough | Not stated | Not stated |
| 02382881 | Cepacol Sensations Sore Throat & Blocked Nose | Not stated | Not stated |
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the data compiled for this report, and no disease-level contraindications were identified from the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no clinical trials, no publications and no plausible mechanism linking a throat antiseptic to cauda equina syndrome. Safety and mechanism data are also missing.
To proceed, the following is needed:
- Mechanism of action data for amylmetacresol (for example from DrugBank)
- Package insert warnings and contraindications from Health Canada
- Preclinical or mechanistic evidence for any candidate indication
- Remapping of the obsolete neurogenic bladder term to a current disease concept, if that candidate is pursued
- Assessment of route compatibility, since the current products are oral lozenges and the predicted indications would need different routes of delivery
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.